Global Array Instruments Market Expected to Reach USD 11.9 Billion by 2031 as Demand Increases in Research and Clinical Genomics
[Boston, 4th June 2025] – Clearview Market Insights (CVMI) projects that the global array instruments market will more than double from USD 5.4 billion in 2024 to USD 11.9 billion by 2031, growing at a compound annual growth rate (CAGR) of 12.1 percent. This growth is driven by increasing demand for personalized medicine, multiplexed diagnostic platforms, and high-throughput drug screening tools across both developed and emerging economies.
“Array-based technologies are evolving from
basic gene expression tools into powerful multi-omics platforms that integrate
genomic, transcriptomic, and proteomic data for precision diagnostics and
therapeutics,” said Dr. Mira Patel, genomics innovation lead at CVMI. “This
shift is unlocking transformative potential in oncology, neurology, rare
disease research, and even agricultural applications.”
Request Sample @ https://clearviewmarketinsights.com/report-details/global-array-instruments-market/
Key Numbers
- 2024
Market Value: USD 5.4 billion
- 2031
Market Value: USD 11.9 billion
- Seven-Year
CAGR: 12.1 percent
- DNA
Arrays Share (2024): 38%
- North
America Share: 42%, Asia-Pacific fastest-growing region
Market Drivers
- Precision
medicine and population-scale screening
- Expansion
of biomarker discovery programs
- Multi-omics
platform integration
- Technological
miniaturization and AI analytics
- Increased
funding from NIH, Horizon Europe, and Asian genomics initiatives
Company Highlights
- Agilent launched high-density rare-variant arrays for translational
genomics.
- Illumina deepened partnerships with government-funded genetic screening
projects.
- Thermo
Fisher connected proteomic array data to cloud
analytics suites for clinical trials.
- Arrayit brought DTC testing kits for protein biomarkers to the consumer
market.
- Bio-Rad introduced ELISA-array hybrids for autoimmune disease detection.
Regional Highlights
- North
America: Sustained investment in genomics infrastructure,
academic trials, and diagnostic innovation.
- Asia-Pacific: Government-led genome sequencing initiatives drive rapid
adoption.
- Europe: IVDR compliance spurs demand for certified clinical-grade array
systems.
- LATAM
& MEA: Market expansion supported by
public-private genomics collaborations and global health donors.
2024–2025 Milestones
Quarter |
Event |
Outcome |
Q1 2024 |
Agilent launches G3 HD arrays |
Enables 50% higher resolution
gene expression profiling |
Q2 2024 |
Thermo Fisher integrates array data into oncology
cloud suite |
Accelerates patient stratification in trials |
Q3 2024 |
Illumina signs regional
genomics pact in Southeast Asia |
Adds 5 million samples to
population genomics pipeline |
Q1 2025 |
Bio-Rad introduces dual-modality ELISA-array
systems |
Improves throughput in autoimmune diagnostics |
For more
insights, visit https://clearviewmarketinsights.com/
About Clearview Market Insights:
Clearview Market Insights is a leading market research and
consulting firm providing in-depth industry analysis and strategic
recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
Comments
Post a Comment